v3.26.1
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
12 Months Ended
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Product Information [Line Items]      
Error corrections of investments in marketable securities   The correction of these error between current and noncurrent assets resulted in an increase in the current asset line item referred to as “Investments in trading securities” and a decrease in the noncurrent line-item referred to as Investment in equity securities by $2,878,000, respectively, from the previously reported amounts of $0 to $2,878,000, and $9,211,000 to $6,333,000, respectively.  
Additional paid-in capital to noncontrolling interests   $ 298.00  
Purchases of marketable securities   316,000 $ 3,327,000
Increase (Decrease) in Interest Payable, Net   2,083,000 3,648,000
Operating activities   (9,129,000) (8,761,000)
Investing activities   18,071,000 12,138,000
Financing activities   (14,059,000) 1,439,000
Allowance for doubtful accounts receivable current   1,014,000 1,613,000
Accounts receivable net current   2,254,000 3,068,000
Allowance for loans losses   7,478,000 9,406,000
Inventory adjustments   53,000 180,000
Inventory raw materials   419,000  
Impairment loss   2,240,000 7,288,000
Impairment of intangible assets $ 600,000 600,000
Other assets     65,000
Goodwill impairment   25,093,000
Goodwill allocation description   Projected cash flows, evaluated using a 26.3% discount rate and 3.0% terminal growth, indicated equity fair value far below the carrying amount, driven by limited historical revenues and sustained operating losses.  
Asset impairment     7,418,000
Impairment of intangible assets     0
Margin loan bears an annual interest rate   8.95%  
Outstanding margin loan   $ 3,569,000 3,295,000
Sales commissions   0 0
Research and development   $ 340,000 $ 278,000
Antidilutive securities   0 0
Cash   $ 6,200,000  
Marketable Securities, Noncurrent   6,517,000 $ 6,333,000
AMRE Life Care Portfolio LLC [Member]      
Product Information [Line Items]      
Real estate assets held for development and sale     41,541,000
Real estate held for development and sale     34,450,000
AMRE Winter Haven LLC [Member]      
Product Information [Line Items]      
Real estate assets held for development and sale     4,396,000
Real estate held for development and sale     4,396,000
AMRE Shelton LLC [Member]      
Product Information [Line Items]      
Real estate held for development and sale     6,313,000
Impact BioMedical, Inc. [Member]      
Product Information [Line Items]      
Goodwill impairment   $ 1,769,000  
UTAH      
Product Information [Line Items]      
Real estate assets held for development and sale     $ 5,593,000
Customer One [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]      
Product Information [Line Items]      
Concentration risk percentage   29.00% 22.00%
Customer Two [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]      
Product Information [Line Items]      
Concentration risk percentage     13.00%
Maximum [Member]      
Product Information [Line Items]      
Operating activities     $ 9,082,000
Investing activities     12,138,000
Financing activities     5,087,000
Minimum [Member]      
Product Information [Line Items]      
Operating activities     8,761,000
Investing activities     8,811,000
Financing activities     1,439,000
Related Party [Member]      
Product Information [Line Items]      
Current portion of long-term debt   $ 188,000 $ 609,000
Reclassification, Other [Member] | Related Party [Member]      
Product Information [Line Items]      
Current portion of long-term debt   $ 5,008,000